Zydus Cadila plans to complete late-stage trials for its novel coronavirus vaccine candidate by February or March and could produce up to 100 million doses a year initially if it is successful, the company chairman said Friday.

Cadila’s vaccine candidate, known as ZyCov-D, is one of dozens being developed around the world to fight the coronavirus pandemic.

“We are looking at about seven or a little more than seven months for the vaccine, provided the data is encouraging and the vaccine is proven to be effective during the trials,” Chairman Pankaj Patel told Reuters in an interview.

“We are also open to discussing partnerships with pharma companies in various geographies, but it is a bit premature right now, and we will be doing so at the end of Phase 1 and 2 trials,” he said.

Early-stage Phase 1 and 2 human trials are likely to be concluded in the next three months, he said.